EGFR and cancer: There is a strong rationale for targeting the EGFR family for cancer treatment: expression/overexpression is frequently seen in carcinomas and brain tumours; overexpression has been shown to correlate with poor outcome in some studies; aberrant signalling through EGFR family is tumorigenic and pharmacological inhibition is associated with tumour inhibition in multiple nonclinical models.